RecruitingPhase 3NCT06084936
Blood
Mantle cell lymphoma
117
studies recruiting now
as of 7 Sept 2026
1,249
studies registered in total
as of 7 Sept 2026
14
countries with a recruiting site
as of 7 Sept 2026
26 Aug 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 3NCT05976763
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
RecruitingPhase 2NCT07029737
A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
RecruitingPhase 1 / Phase 2NCT07788118
A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
RecruitingPhase 1NCT07691606
A Study of ARC-02 in B-cell NHL
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 117 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Mantle cell lymphoma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Mantle cell lymphoma
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (CCND1, ATM, IGH).
Treatments being studied
12 approved treatments and 60 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Temsirolimus (Torisel)Approved: Zanubrutinib (Brukinsa)Approved: Acalabrutinib Maleate (Calquence)Approved: AcalabrutinibApproved: Pirtobrutinib (Jaypirca)Approved: Ibrutinib (Imbruvica)Approved: Lenalidomide Hydrochloride Monohydrate (Lenalidomide krka (previously lenalidomide krka d.d. novo mesto))Approved: BortezomibApproved: Bendamustine Hydrochloride (Belrapzo)Approved: Lenalidomide (Lenalidomide accord)Approved: Brexucabtagene Autoleucel (Tecartus)Approved: Bortezomib D-Mannitol (Bortezomib accord)
Phase 3Fludarabine
Phase 3Cisplatin (Cisplatin)
Phase 3Bendamustine
Phase 3Dexamethasone (Aeroseb-dex)
Phase 3Doxorubicin (Adriblastina)
Phase 3Cytarabine (Alexan)
Phase 3Parsaclisib
Phase 3Vincristine Sulfate (Leurocristine sulfate)
+ 52 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).